NewsBenzingaHC Wainwright & Co. Reitera su recomendación de compra sobre Halozyme Therapeutics y mantiene un precio objetivo de 130 dólares HC Wainwright & Co. Reitera su recomendación de compra sobre Halozyme Therapeutics y mantiene un precio objetivo de 130 dólares Benzinga 2026.11.20 11:32 (GMT+0) Open on Benzinga Other news Keybanc Downgrades BILL Holdings to Sector Weight William Blair Upgrades Pyxis Oncology to Outperform BTIG Reiterates Buy on Walmart, Maintains $140 Price Target Procter & Gamble Plans up to 30% Supply Job Cuts by 2030, Aims for $10 Billion in Cost Savings Mark Cuban Says Healthcare Economics Run On ‘Contractual Terrorism’: ‘Even the Biggest Companies Get Ripped Off’ Hewlett Packard Enterprise Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Mark Cuban Says Healthcare Economics Run On ‘Contractual Terrorism’: ‘Even the Biggest Companies Get Ripped Off’
Hewlett Packard Enterprise Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call